Double Point Ventures and DCVC Bio co-led a $100m Series C round in Umoja Biopharma.

Double Point Ventures, a venture capital firm, and DCVC Bio, also a venture capital firm, co-led a $100m Series C round in Umoja Biopharma, a biotechnology company, with particiaption from ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, and University of Minnesota Endowment. “This Series C fundraise demonstrates both the progress and significant potential of Umoja’s in vivo oncology programs, including UB-VV400 and UB-VV111," Scott Myers, Umoja Biopharma CEO.